BioSpace News Archive

Century Therapeutics, Inc., an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, reported financial results and business highlights for the third quarter ended September 30, 2023.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the quarter ended September 30, 2023.

Immunovant, Inc. reported corporate updates and financial results for its fiscal second quarter ended September 30, 2023.

Zentalis® Pharmaceuticals, Inc. announced that Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis, and Melissa Epperly, MBA, Chief Financial Officer of Zentalis, will be joined by gynecologic oncology key opinion leader, Joyce F. Liu, M.D., MPH, for an investor call on Friday, November 10th, at 10:00 a.m. ET hosted by TD Cowen to discuss the azenosertib ovarian cancer clinical updates.

Senhwa Biosciences, Inc. announced that their first patient has been successfully dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19.

March Biosciences and Cancer Focus Fund, LP announced that Cancer Focus Fund is investing $4.8 million in funding and providing clinical support for March Bio’s upcoming Phase 2 clinical trial of MB-105 for the treatment of relapsed T-cell leukemias and lymphomas.

Eccogene announced that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogene’s small molecule GLP-1 receptor agonist ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities.

CalciMedica Inc. reported financial results for the third quarter ended September 30, 2023.

Terray Therapeutics announced an equity investment by NVentures, NVIDIA’s venture capital arm.